Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.molecularpartners.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2022 | Outperform → Sector Perform | RBC Capital Mkts | |
| 8/29/2022 | $30.00 → $8.00 | Outperform → Mkt Perform | SVB Leerink |
| 5/25/2022 | Underperform → Neutral | Credit Suisse | |
| 4/27/2022 | Neutral → Underperform | Credit Suisse |
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
424B5 - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
S-8 - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K/A - MOLECULAR PARTNERS AG (0001745114) (Filer)
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317's ability to activate CD40 in a variety of tumor types further evidenced by comprehensive clinical biomarker analyses ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the presentation of data pertaining to two programs, including preclinical proof-of-concept for a novel T cell
Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin MP0621 demonstrates cKit+ cell killing while reducing off-target effects seen with systemic anti-CD47 blockade ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of data from its MP0533 and MP0621 programs at the upcoming Annual Meeting of the American Society of
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025 RDT strategic agreement with Orano Med revised and strengthened: both companies to co-develop four 212Pb-based RDT candidates, including MP0712 MP0533 phase 1 dose escalation study continues; update to be presented at the American Society for Hematology Annual Meeting (ASH); protocol being amended to improve treatment exposure CD3 Switch-DARPin proof-of-mechanism to be presented at the Society for the Immunotherapy of Cancer Annual Meeting (SITC); update on Switch-DARPin MP06
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the pricing of an underwritten offering in the United States of 3,642,988 American Depositary Shares ("ADSs") representing 3,642,988 ordinary shares at an offering price of $5.49 per ADS, for total gross proceeds of approximately $20.0 million. All of the ADSs to be sold in the offering will be offered by Molecular Partners. The offering is expec
Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each)Molecular Partners will hold commercial rights to the second nominated Radio-DARPin Candidate, in addition to rights to first program MP0712 targeting DLL3 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the strengthening
Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision attributes for alpha radiation therapy Molecular Partners and Orano Med preparing for clinical entry in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a clinical-stage radiopharmaceutical company developing targeted alpha t
Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40) shows intended and marked tumor microenvironment modulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will introduce proof-of-concept data for its new CD3 Switch-DARPin designed to overcome current T cell engager challenges in solid tumors, as well as presen
First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present on its lead-212 (212Pb)-labeled Radio-DARPin Therapeutic (RDT) targeting delta-like ligand 3 (DLL3) co-developed with Orano Med, at the European Assocation of Nuclear Medicine (EANM) Congress which runs
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announce that the Company will present in a fireside chat at the 2nd TD Cowen Radiopharmaceutical Innovation Summit today, June 17, 2024 at 10:40 a.m. ET (4:40 p.m. CET). Presenting on behalf of Molecular Partners will be Michael Stumpp, Ph.D., Executive Vice President, and co-founder of Molecular Partners. A live webcast of the event will be available on the "News and Events" page in the "Events" section of the Company's website. A replay of t
Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activatorsPreclinical safety, efficacy, and pharmacokinetics support MP0621's potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effectsMP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced
SC 13D/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13D - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13G/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13G/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
RBC Capital Mkts downgraded Molecular Partners AG from Outperform to Sector Perform
SVB Leerink downgraded Molecular Partners AG from Outperform to Mkt Perform and set a new price target of $8.00 from $30.00 previously
Credit Suisse upgraded Molecular Partners AG from Underperform to Neutral
Credit Suisse downgraded Molecular Partners AG from Neutral to Underperform
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results. Molecular Partners' Chief Executive Officer Patrick Amstutz will also present at the 44th Annual Cowen Health Care Conference taking place in Boston, MA, and will participate in the Leerink Global Biopharma Conference taking place in Miami, FL along with oth
Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm proposed MOA and indicates favorable safety profile in patients with advanced solid tumors, supporting future combination studies with potential partners; presently finalizing recruitment of weekly dosing regimen Preclinical data supporting the Radio DARPin Therapy platform presented at leading conferences TAT12, AACR and SNMMI in H1 2023 Funded well into 2026 with cash of CHF 218 million as of June 30
Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)Presented preclinical data supporting the unique design and mechanism of MP0533 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionEstablished Radio DARPin Therapy (RDT) Platform, formally selecting tumor-associated protein Delta-like ligand 3 (DLL3) as a first targetPresented interim safety and mechanism data from ongoing Phase 1 study of MP0317 for the treatment of solid tumors at the 37th Society for Immunotherapy of Cancer (SITC) Annual MeetingSigned in early Janu
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the fourth quarter and full year of 2022, followed by an investor call the following day. Chief Executive Officer Patrick Amstutz will also deliver a company presentation at the 43rd Annual Cowen Health Care Conference in Boston, MA. Please see all details below: Conference Presentation Details: Cowen Health Care ConferenceMarch 8, 2023, at 9:10am ET (3:10pm CET)B
Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of proprietary DARPin-conjugated radioligand therapeutics; innate immune cell engagers; next-generation T-cell engagers; and antiviral DARPinsMP0310 Phase 1 enrollment complete; no additional studies currently plannedIn January 2022, Molecular Partners received a payment of CHF 150 million from Novartis to license ensovibepNovartis is responsible for further development, manufacturing, and commercialization activities. An application for Emergency Use Authorization (EUA) was submitted to the U.S. Foo
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the first half-year of 2022, followed by an analyst & investor call the following day. Please see more details here: Release date and time August 25, 2022, 4:30 pm ET (10:30 pm CET) Call Details: August 26, 2022, 8:00 am ET (2:00 pm CET) The half year 2022 results presentation will be webcast live and will be made available on the Company's website under the inv
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in two upcoming healthcare investor events in March, 2022. In addition, the Company will publish its full year 2021 annual report on March 15 and hold an investor conference call on March 16, 2021. Presentation Details: Cowen Health Care Conference – Fireside chat Wednesday, March 9, 2022 at 2:10-2:40pm ET Conference Participation Detai
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday. Shares of ResMed Inc. (NYSE:RMD) fell sharply during Monday's session following sleep apnea data from Lilly. Citigroup analyst Mathieu Chevrier downgraded ResMed from Buy to Neutral. ResMed shares dipped 10.4% to $184.35 on Monday. Here are some other big stocks recording gains in today’s session. Molecular Partners AG (NASDAQ:MOLN) shares dipped 22.6% to $7.43. Cryoport, Inc. (NASDAQ:CYRX) fell 19.9% to $7.77. Cryoport announced a strategic partnership with Minaris Regenerative Medicine for cell and gene therapies advancement. BridgeBio Pharma, Inc. (NASDAQ:BBIO) dipped 19.2% to $22.1
Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0 million public offering. Kaival Brands priced its 3,921,500 unit offering at $15.3 per unit. Kaival Brands Innovations Group shares dipped 47% to $1.52 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers American Rebel Holdings, Inc. (NASDAQ:AREB) shares jumped 161% to $0.8048 after the company signed a Connecticut distribution agreement with Dichello Distributors. Sharecare, Inc. (NASDAQ:SHCR) jumped 74% to $1.35 after the company agreed to be acquired by Altaris affiliate for $1.43 per share in cash.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above. Sarepta Therapeutics shares climbed 35.2% to $166.96 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Spectaire Holdings Inc (NASDAQ:SPEC) rose 110% to $0.7140 in pre-market trading after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy. DermTech, Inc. (NASDAQ:DMTK) gained 105.5% to $0.2423 in pre-market trading after declining 19% on Thursday. DermTech recently filed f
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Friday. Shares of Smith & Wesson Brands, Inc. (NASDAQ:SWBI) fell sharply in today's pre-market trading after the company reported its fourth-quarter financial results. Smith & Wesson reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 34 cents. Quarterly sales came in at $159.1 million, which beat the analyst consensus estimate of $156.796 million, according to data from Benzinga Pro. Smith & Wesson Brands shares fell 4% to $15.74 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Mole
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA
Gainers Molecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. Zentalis Pharma (NASDAQ:ZNTL) stock rose 36.83% to $5.67. The market value of their outstanding shares is at $402.2 million. Femasys (NASDAQ:FEMY) stock increased by 28.27% to $1.23. The market value of their outstanding shares is at $27.2 million. SeaStar Medical Holding (NASDAQ:ICU) shares rose 18.68% to $4.89. The market value of their outstanding shares is at $15.2 million. Nanoviricides (AMEX:NNVC) shares rose 17.68% to $1.93. The company's market cap stands at $22.8 million. CASI Pharmaceuticals (NASDAQ:CASI) sha
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses. Vuzix shares jumped 15% to $1.53 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers SMX (Security Matters) Public Limited Company (NASDAQ:SMX) rose 109.8% to $0.2497 in pre-market trading after jumping 19% on Tuesday. Selina Hospitality PLC (NASDAQ:SLNA) gained 46.9% to $0.1024 in pre-market trading after declining 7% on Tuesday. Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 44.5%
Gainers Tempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday's pre-market session. The company's market cap stands at $84.0 million. Neurogene (NASDAQ:NGNE) shares rose 31.92% to $40.0. The company's market cap stands at $519.2 million. Geovax Labs (NASDAQ:GOVX) shares rose 28.94% to $2.45. The company's market cap stands at $6.1 million. SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 24.03% to $3.2. The market value of their outstanding shares is at $29.5 million. Trevena (NASDAQ:TRVN) stock rose 23.33% to $0.44. The market value of their outstanding shares is at $8.0 million. Molecular Partners (NASDAQ:MOLN) stock rose 22.23% to $9.73. The company's
ADBE: 16% | Adobe shares are trading higher following better-than-expected Q2 earnings and strong guidance. BPTH: 46% | Bio-Path Holdings shares are trading higher after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia. MOLN: 14% | Molecular Partners shares are trading higher after the comapny announced preclinical proof-of-concept data from MP0621.
Gainers Ainos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 34.15% to $3.61. The company's market cap stands at $22.9 million. Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 20.99% to $2.42. The market value of their outstanding shares is at $4.4 million. Moleculin Biotech (NASDAQ:MBRX) stock moved upwards by 17.24% to $5.1. The market value of their outstanding shares is at $11.7 million. Tonix Pharmaceuticals (NASDAQ:TNXP) shares moved upwards by 12.84% to $1.23. The company's market cap stands at $3.6 million. Molecular Partners (NASDAQ:MO